Releases

Date Title and Summary Additional Formats
Toggle Summary Veloxis Pharmaceuticals Announces Updated Financial Calendar for 2015
Company Announcement no. 3/2015     To: NASDAQ OMX Copenhagen A/S                          Hørsholm, Denmark, 21 January 2015    Veloxis Pharmaceuticals Announces Updated Financial Calendar for 2015   Veloxis Pharmaceuticals A/S (OMX: VELO) today announces updated financial calendar for 2015.
View HTML
Toggle Summary U.S. District Court Sets Briefing Schedule in Veloxis Litigation
Company Announcement no. 2/2015    To: NASDAQ OMX Copenhagen A/S                                Hørsholm, Denmark, 14 January 2015   U.S. District Court Sets Briefing Schedule in Veloxis Litigation   Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) today confirmed that the U.S.
View HTML
Toggle Summary Amerikansk distriktsdomstol fastlægger tidsplan for skriftvekslinger i Veloxis' retssag
Selskabsmeddelelse nr. 2/2015     Til: NASDAQ OMX Copenhagen A/S                              Hørsholm, den 14. januar 2015     Amerikansk distriktsdomstol fastlægger tidsplan for skriftvekslinger i Veloxis' retssag   Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) har i dag bekræftet, at
View HTML
Toggle Summary Veloxis har modtaget afgørelse fra den amerikanske sundhedsmyndighed (FDA)
Selskabsmeddelelse nr. 1/2015    Til: NASDAQ OMX Copenhagen A/S                              Hørsholm, den 13. januar 2015   Veloxis har modtaget afgørelse fra den amerikanske sundhedsmyndighed (FDA)   Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) har i dag bekræftet at have modtaget besked fra
View HTML
Toggle Summary Veloxis Confirms Receipt of U.S. Food and Drug Administration Decision
Company Announcement no. 1/2015    To: NASDAQ OMX Copenhagen A/S                                Hørsholm, Denmark, 13 January 2015     Veloxis Confirms Receipt of U.S. Food and Drug Administration Decision     Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) today confirmed that it has received
View HTML
Toggle Summary Veloxis kommenterer kendelse fra amerikansk distriktsdomstol
Selskabsmeddelelse nr. 29/2014     Til: NASDAQ OMX Copenhagen A/S                              Hørsholm, den 19. december 2014     Veloxis kommenterer kendelse fra amerikansk distriktsdomstol   Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) har i dag offentliggjort følgende udtalelse
View HTML
Toggle Summary Veloxis Comments on U.S. District Court Order
Company Announcement no. 29/2014     To: NASDAQ OMX Copenhagen A/S                              Hørsholm, Denmark, 19 December 2014     Veloxis Comments on U.S. District Court Order   Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) today issued the following statement regarding an order issued by
View HTML
Toggle Summary Veloxis announces that it has filed an action against the Food and Drug Administration, seeking an order requiring FDA to grant final approval to Envarsus® XR.
Company Announcement no. 28/2014    To: NASDAQ OMX Copenhagen A/S                              Hørsholm, Denmark, 16 December 2014    Veloxis announces that it has filed an action against the Food and Drug Administration, seeking an order requiring FDA to grant final approval to Envarsus® XR.
View HTML
Toggle Summary Veloxis offentliggør at have anlagt retssag mod de amerikanske sundhedsmyndigheder FDA med påstand om, at FDA skal tilpligtes at udstede endelig godkendelse af Envarsus® XR.
Selskabsmeddelelse nr. 28/2014   Til: NASDAQ OMX Copenhagen A/S                               Hørsholm, 16. december 2014    Veloxis offentliggør at have anlagt retssag mod de amerikanske sundhedsmyndigheder FDA med påstand om, at FDA skal tilpligtes at udstede endelig godkendelse af Envarsus ® XR.
View HTML
Toggle Summary Veloxis Pharmaceuticals Announces Financial Calendar for 2015
Company Announcement no. 27/2014   To: NASDAQ OMX Copenhagen A/S                                Hørsholm, Denmark, 16 December 2014   Veloxis Pharmaceuticals Announces Financial Calendar for 2015   Veloxis Pharmaceuticals A/S (OMX: VELO) today announced financial calendar for 2015.   4.
View HTML
Toggle Summary Veloxis Pharmaceuticals offentliggør finanskalendar for 2015
Selskabsmeddelelse nr. 27/2014    Til: NASDAQ OMX Copenhagen A/S                                         Hørsholm, den 16. december 2014    Veloxis Pharmaceuticals offentliggør finanskalendar for 2015   Veloxis Pharmaceuticals A/S (OMX: VELO) har i dag offentliggjort finanskalendar for 2015.
View HTML
Toggle Summary Veloxis Announces Publication of Phase III Study of Once Daily Envarsus® XR Demonstrating Non-Inferiority vs. Twice-Daily Tacrolimus in De Novo Kidney Transplant Patients
Investor service announcement no. 8/2014   To: NASDAQ OMX Copenhagen                   Hørsholm, Denmark, 17 November, 2014   Veloxis Announces Publication of Phase III Study of Once Daily Envarsus ® XR Demonstrating Non-Inferiority vs. Twice-Daily Tacrolimus in De Novo Kidney Transplant Patients  
View HTML
Toggle Summary Warrantordning - Nye vedtægter
Selskabsmeddelelse nr. 26/2014     Til: NASDAQ OMX Copenhagen A/S                                          Hørsholm, den 17. november 2014      Warrantordning - Nye vedtægter   Bestyrelsen i Veloxis Pharmaceuticals A/S har i henhold til bemyndigelsen i vedtægternes § 5A, den 12.
View HTML
Toggle Summary Warrant Programme - New Articles of Association
Company Announcement no. 26/2014   To: NASDAQ OMX Copenhagen A/S                                  Hørsholm, Denmark, 17 November 2014    Warrant Programme - New Articles of Association   In accordance with its authorisation pursuant to Section 5A of the Articles of Association, the Board of
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S establishes new Warrant Programme
Company Announcement no. 25/2014     To: NASDAQ OMX Copenhagen A/S                             Hørsholm, Denmark, 12 November 2014     Veloxis Pharmaceuticals A/S establishes new Warrant Programme   Today, the Board of Directors of Veloxis has decided to establish a new warrant programme for new
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S etablerer warrantordning
Selskabsmeddelelse nr. 25/2014   Til: NASDAQ OMX Copenhagen A/S                                      Hørsholm, den 12 november 2014      Veloxis Pharmaceuticals A/S etablerer warrantordning   Bestyrelsen i Veloxis Pharmaceuticals A/S har i dag besluttet at etablere en warrantordning for nye
View HTML
Toggle Summary Veloxis Pharmaceuticals announces financial results for the first nine months of 2014 and improves the full year outlook
Company Announcement no. 24/2014   To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 12 November, 2014    Veloxis Pharmaceuticals announces financial results for the first nine months of 2014 and improves the full year outlook   Highlights:   On 31 October the U.S.
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af kvartalsrapporten for 3. kvartal 2014 — resultater fra 1. januar til 30. september 2014
Investor service meddelelse nr. 7/2014    Til: NASDAQ OMX København                                     Hørsholm, den 7 november 2014    Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af kvartalsrapporten for 3. kvartal 2014 — resultater fra 1.
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for third Quarter 2014 — results from 1 January to 30 September, 2014
Investor service announcement no. 7/2014    To: NASDAQ OMX Copenhagen                         Hørsholm, Denmark, 7 November, 2014    Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for third Quarter 2014 — results from 1 January to 30 September, 2014   Veloxis
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S to Host Conference Call discussing the FDA tentative approval of Envarsus® XR
Investor service announcement no. 6/2014   To: NASDAQ OMX Copenhagen                         Hørsholm, Denmark, 31 October, 2014    Veloxis Pharmaceuticals A/S to Host Conference Call discussing the FDA tentative approval of Envarsus ® XR   Veloxis Pharmaceuticals A/S (OMX: VELO) Veloxis'
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S er vært for en telekonference for at diskutere den foreløbige godkendelse af Envarsus® XR
Investor service meddelelse nr. 6/2014   Til: NASDAQ OMX København                                     Hørsholm, den 31 oktober 2014    Veloxis Pharmaceuticals A/S er vært for en telekonference for at diskutere den foreløbige godkendelse af Envarsus ® XR   Veloxis Pharmaceuticals A/S (OMX: VELO)
View HTML
Toggle Summary Veloxis modtager foreløbig godkendelse for Envarsus® XR
Selskabsmeddelelse nr. 23/2014     Til: NASDAQ OMX Copenhagen A/S                                  Hørsholm, 31. oktober 2014     Veloxis modtager foreløbig godkendelse for Envarsus ® XR FDA anfører at godkendelsen ikke vil være endelig før eksklusiviteten for Astagraf XL ® udløber Veloxis
View HTML
Toggle Summary Veloxis announces tentative approval of Envarsus® XR
Company Announcement no. 23/2014     To: NASDAQ OMX Copenhagen A/S                                  Hørsholm, Denmark, 31 October 2014     Veloxis announces tentative approval of Envarsus ® XR FDA states that approval will not be final until Astagraf XL® exclusivity expires; Veloxis is appealing
View HTML
Toggle Summary Warrant Programme - New Articles of Association
Company Announcement no. 22/2014   To: NASDAQ OMX Copenhagen A/S                                     Hørsholm, Denmark, 2 September 2014      Warrant Programme - New Articles of Association    In accordance with its authorisation pursuant to Section 5A of the Articles of Association, the Board of
View HTML
Toggle Summary Warrantordning - Nye vedtægter
Selskabsmeddelelse nr. 22/2014    Til: NASDAQ OMX Copenhagen A/S                                             Hørsholm, den 2. september 2014      Warrantordning - Nye vedtægter     Bestyrelsen i Veloxis Pharmaceuticals A/S har i henhold til bemyndigelsen i vedtægternes § 5A, den 20.
View HTML
Toggle Summary Warrant Program - Registrering af kapitalforhøjelse og nye vedtægter i forlængelse af warrantudnyttelse
Selskabsmeddelelse nr. 21/2014     Til: NASDAQ OMX Copenhagen A/S                                          Hørsholm, den 1 september 2014     Warrant Program - Registrering af kapitalforhøjelse og nye vedtægter i forlængelse af warrantudnyttelse     Med reference til selskabsmeddelelse nr.
View HTML
Toggle Summary Warrant Programme - Registration of capital increase and new Articles of Association following warrant exercise
Company Announcement no. 21/2014     To: NASDAQ OMX Copenhagen A/S                                  Hørsholm, Denmark, 1 september 2014      Warrant Programme - Registration of capital increase and new Articles of Association following warrant exercise   With reference to Company Announcement no.
View HTML
Toggle Summary Warrant Programme - Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants
Company Announcement no. 20/2014   To: NASDAQ OMX Copenhagen A/S                             Hørsholm, Denmark, 1 September 2014      Warrant Programme - Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants   Veloxis Pharmaceuticals A/S announces that the company's
View HTML
Toggle Summary Warrantprogram - Veloxis Pharmaceuticals A/S udsteder nye aktier i forbindelse med udnyttelse af warrants
Selskabsmeddelelse nr. 20/2014     Til: NASDAQ OMX Copenhagen A/S                                      Hørsholm, den 1. september 2014     Warrantprogram - Veloxis Pharmaceuticals A/S udsteder nye aktier i forbindelse med udnyttelse af warrants   Veloxis Pharmaceuticals A/S meddeler hermed, at
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S establishes new Warrant Programme
Company Announcement no. 19/2014     To: NASDAQ OMX Copenhagen A/S                             Hørsholm, Denmark, 20 august 2014     Veloxis Pharmaceuticals A/S establishes new Warrant Programme   Today, the Board of Directors of Veloxis has decided to establish a new warrant programme for new
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S etablerer warrantordning
Selskabsmeddelelse nr. 19/2014   Til: NASDAQ OMX Copenhagen A/S                                      Hørsholm, den 20. august 2014      Veloxis Pharmaceuticals A/S etablerer warrantordning   Bestyrelsen i Veloxis Pharmaceuticals A/S har i dag besluttet at etablere en warrantordning for nye
View HTML
Toggle Summary Veloxis Pharmaceuticals announces financial results for the first six months of 2014
Company Announcement no. 18/2014   To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 20 August, 2014     Veloxis Pharmaceuticals announces financial results for the first six months of 2014   Highlights:   On 28 July the European Commission granted marketing authorization for Envarsus® for the
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for second Quarter 2014 — results from 1 January to 30 June, 2014
Investor service announcement no. 5/2014    To: NASDAQ OMX Copenhagen                         Hørsholm, Denmark, 15 August, 2014      Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for second Quarter 2014 — results from 1 January to 30 June, 2014   Veloxis
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af kvartalsrapporten for 2. kvartal 2014 — resultater fra 1. januar til 30. juni 2014
Investor service meddelelse nr. 5/2014   Til: NASDAQ OMX København                                     Hørsholm, den 15 august 2014   Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af kvartalsrapporten for 2. kvartal 2014 — resultater fra 1.
View HTML
Toggle Summary Envarsus® får EMA markedføringstilladelse til behandling af såvel nyre- som levertransplantationspatienter
Selskabsmeddelelse nr. 17/2014     Til: NASDAQ OMX Copenhagen A/S                                  Hørsholm, 28. juli 2014     Envarsus ® får EMA markedføringstilladelse til behandling af såvel nyre- som levertransplantationspatienter   Veloxis Pharmaceuticals A/S (OMX: VELO) og Chiesi Farmaceutici
View HTML
Toggle Summary Envarsus® Receives European Marketing Authorization for Treatment of Both Kidney and Liver Transplant Patients
Company Announcement no. 17/2014   To: NASDAQ OMX Copenhagen A/S                      Hørsholm, Denmark, 28 July 2014    Envarsus ® Receives European Marketing Authorization for Treatment of Both Kidney and Liver Transplant Patients    Veloxis Pharmaceuticals A/S (OMX: VELO) and Chiesi Farmaceutici
View HTML
Toggle Summary Envarsus® XR viser lavere forekomst af behandlingssvigt i afroamerikanere sammenlignet med to-gange-daglig tacrolimus (Prograf®)
Selskabsmeddelelse nr. 16/2014   Til: NASDAQ OMX Copenhagen A/S                                  Hørsholm, 30. juni 2014      Envarsus ® XR viser lavere forekomst af behandlingssvigt i afroamerikanere sammenlignet med to-gange-daglig tacrolimus (Prograf ® )   Resultatet er set på tværs af stabile
View HTML
Toggle Summary Envarsus® XR Demonstrates Lower Treatment Failure Rate in African-Americans Compared to Twice-Daily Tacrolimus (Prograf®)
Company Announcement no. 16/2014    To: NASDAQ OMX Copenhagen A/S                      Hørsholm, Denmark, 30 June 2014      Envarsus ® XR Demonstrates Lower Treatment Failure Rate in African-Americans Compared to Twice-Daily Tacrolimus (Prograf ® )   Result seen across stable and de novo kidney
View HTML
Toggle Summary Veloxis Announces Positive Two-Year Results from Pivotal Phase 3 Study of Envarsus® XR (tacrolimus extended-release tablets) in de novo Kidney Transplant Patients
Company Announcement no. 15/2014   To: NASDAQ OMX Copenhagen A/S                      Hørsholm, Denmark, 23 June 2014   Veloxis Announces Positive Two-Year Results from Pivotal Phase 3 Study of Envarsus ® XR (tacrolimus extended-release tablets) in de novo Kidney Transplant Patients   Veloxis
View HTML
Toggle Summary Veloxis offentliggør positive 2-års resultater af pivotalt fase III studie af Envarsus® XR (tacrolimus extended-release tabletter) i de novo nyretransplantationspatienter
Selskabsmeddelelse nr. 15/2014    Til: NASDAQ OMX Copenhagen A/S                               Hørsholm, 23. juni 2014    Veloxis offentliggør positive 2-års resultater af pivotalt fase III studie af Envarsus ® XR (tacrolimus extended-release tabletter) i de novo nyretransplantationspatienter  
View HTML
Toggle Summary Veloxis Announces Senior Level Appointments in Preparation for U.S. Commercialization of Envarsus® XR (tacrolimus extended-release tablets)
Investor service announcement no. 4/2014   To: NASDAQ OMX Copenhagen A/S                   Hørsholm, Denmark, 3 June 2014    Veloxis Announces Senior Level Appointments in Preparation for U.S. Commercialization of Envarsus ® XR (tacrolimus extended-release tablets)   Veloxis Pharmaceuticals A/S
View HTML
Toggle Summary Warrant Programme - New Articles of Association
Company Announcement no. 14/2014    To: NASDAQ OMX Copenhagen A/S                                  Hørsholm, Denmark, 22 May 2014      Warrant Programme - New Articles of Association   In accordance with its authorisation pursuant to Section 5A of the Articles of Association, the Board of Directors
View HTML
Toggle Summary Warrantordning - Nye vedtægter
Selskabsmeddelelse nr. 14/2014   Til: NASDAQ OMX Copenhagen A/S                                          Hørsholm, den 22. maj 2014      Warrantordning - Nye vedtægter   Bestyrelsen i Veloxis Pharmaceuticals A/S har i henhold til bemyndigelsen i vedtægternes § 5A, den 14.
View HTML
Toggle Summary Veloxis Receives Positive Opinion from CHMP for Envarsus® for Treatment of Both Kidney and Liver Transplant Patients
Company Announcement no. 13/2014   To: NASDAQ OMX Copenhagen A/S                      Hørsholm, Denmark, 22 May 2014    Veloxis Receives Positive Opinion from CHMP for Envarsus ® for Treatment of Both Kidney and Liver Transplant Patients    Veloxis Pharmaceuticals A/S (OMX: VELO) today announced
View HTML
Toggle Summary Veloxis modtager positiv udtalelse fra CHMP for Envarsus® til behandling af såvel nyre- som levertransplantationspatienter
Selskabsmeddelelse nr. 13/2014   Til: NASDAQ OMX Copenhagen A/S                               Hørsholm, 22. maj 2014    Veloxis modtager positiv udtalelse fra CHMP for Envarsus ® til behandling af såvel nyre- som levertransplantationspatienter   Veloxis Pharmaceuticals A/S (OMX: VELO) har i dag
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S establishes new Warrant Programme
Company Announcement no. 12/2014    To: NASDAQ OMX Copenhagen A/S                             Hørsholm, Denmark, 14 May 2014    Veloxis Pharmaceuticals A/S establishes new Warrant Programme   Today, the Board of Directors of Veloxis has decided to establish a new warrant programme for new employees
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S etablerer warrantordning
Selskabsmeddelelse nr. 12/2014    Til: NASDAQ OMX Copenhagen A/S                                      Hørsholm, den 14. maj 2014      Veloxis Pharmaceuticals A/S etablerer warrantordning   Bestyrelsen i Veloxis Pharmaceuticals A/S har i dag besluttet at etablere en warrantordning for nye
View HTML
Toggle Summary Veloxis Pharmaceuticals announces financial results for the first three months of 2014
Company Announcement no. 11/2014   To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 14 May, 2014    Veloxis Pharmaceuticals announces financial results for the first three months of 2014   Highlights:   The U.S. Food and Drug Administration (FDA) has accepted for standard review the company's New
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af kvartalsrapporten for 1. kvartal 2014 — resultater fra 1. januar til 31. marts 2014
Investor service meddelelse nr. 3/2013    Til: NASDAQ OMX København                                     Hørsholm, den 6 maj 2014    Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af kvartalsrapporten for 1. kvartal 2014 — resultater fra 1.
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for first Quarter 2014 — results from 1 January to 31 March, 2014
Investor service announcement no. 3/2014   To: NASDAQ OMX Copenhagen                         Hørsholm, Denmark, 6 May, 2014   Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for first Quarter 2014 — results from 1 January to 31 March, 2014   Veloxis Pharmaceuticals A/S
View HTML